SCHAFFER DAVID 4
4 · 4D Molecular Therapeutics Inc. · Filed Oct 1, 2021
Insider Transaction Report
Form 4
SCHAFFER DAVID
Director10% Owner
Transactions
- Sale
Common Stock
2021-09-29$29.06/sh−8,365$243,058→ 950,585 total - Sale
Common Stock
2021-09-29$30.06/sh−700$21,044→ 949,885 total - Sale
Common Stock
2021-09-29$27.99/sh−7,806$218,512→ 958,950 total - Sale
Common Stock
2021-09-30$26.69/sh−7,836$209,165→ 942,049 total - Sale
Common Stock
2021-09-30$27.28/sh−4,549$124,085→ 937,500 total
Footnotes (6)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- [F2]The transaction was executed in multiple trades in prices ranging from $27.70 to $28.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]The transaction was executed in multiple trades in prices ranging from $28.71 to $29.69, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]The transaction was executed in multiple trades in prices ranging from $29.75 to $30.66, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F5]The transaction was executed in multiple trades in prices ranging from $26.07 to $27.06, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F6]The transaction was executed in multiple trades in prices ranging from $27.08 to $27.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.